How many insider trades does FilingIQ track for CLYM?

FilingIQ tracks 27 Form 4 insider transactions for CLYM (Climb Bio, Inc.), covering filings from Dec 20, 2024 onwards. 5 of those are dated within the last 90 days.

Are CLYM insiders net buyers or net sellers?

Across the full Form 4 history for CLYM, 3 transactions (11%) were open-market purchases and 10 (37%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does CLYM insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is CLYM in?

Climb Bio, Inc. (CLYM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $382.51M.

CLYM insider trading

Healthcare

Climb Bio, Inc.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

Last 90 days

Buys / sells

11% / 37%

Market cap

$382.51M

About Climb Bio, Inc.

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN). The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Company website: climbbio.com

CLYM insider activity at a glance

FilingIQ tracks 27 insider transactions for CLYM in filings since Dec 20, 2024. The most recent transaction is dated Sep 28, 2026.

Across the full history, 3 open-market purchases and 10 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on CLYM insider trades is 57.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live CLYM trades on FilingIQ Raw filings on SEC EDGAR

Latest CLYM Form 4 filings

RA CAPITAL MANAGEMENT, L.P.

M Sep 30, 2026

Thomas Stephen Basil

S Sep 17, 2026

RA CAPITAL MANAGEMENT, L.P.

A Jul 1, 2026

Celebi Breanna Maurine

A Jul 1, 2026

Brennan Aoife President and CEO

SM Jun 30, 2026

RA CAPITAL MANAGEMENT, L.P.

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 820

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

CORT 110

CORCEPT THERAPEUTICS INC

TEM 104

Tempus AI, Inc.

Frequently asked

How many insider trades does FilingIQ track for CLYM?: FilingIQ tracks 27 Form 4 insider transactions for CLYM (Climb Bio, Inc.), covering filings from Dec 20, 2024 onwards. 5 of those are dated within the last 90 days.
Are CLYM insiders net buyers or net sellers?: Across the full Form 4 history for CLYM, 3 transactions (11%) were open-market purchases and 10 (37%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CLYM insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is CLYM in?: Climb Bio, Inc. (CLYM) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $382.51M.

Methodology & sources

Every CLYM insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.